KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Non-Current Deffered Revenue (2017 - 2025)

Bionano Genomics' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $192000.0 for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 27.0% year-over-year to $192000.0; the TTM value through Sep 2025 reached $192000.0, down 27.0%, while the annual FY2024 figure was $267000.0, 73.38% up from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $192000.0 at Bionano Genomics, down from $243000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $292000.0 in Q1 2025 and bottomed at $108000.0 in Q1 2021.
  • The 5-year median for Non-Current Deffered Revenue is $186000.0 (2023), against an average of $188210.5.
  • The largest annual shift saw Non-Current Deffered Revenue soared 153.57% in 2021 before it fell 28.87% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $146000.0 in 2021, then decreased by 13.01% to $127000.0 in 2022, then rose by 21.26% to $154000.0 in 2023, then surged by 73.38% to $267000.0 in 2024, then dropped by 28.09% to $192000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Non-Current Deffered Revenue are $192000.0 (Q3 2025), $243000.0 (Q2 2025), and $292000.0 (Q1 2025).